Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc trimmed its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 10.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 73,473 shares of the biopharmaceutical company’s stock after selling 8,297 shares during the quarter. Ensign Peak Advisors Inc’s holdings in Alnylam Pharmaceuticals were worth $17,854,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in ALNY. Allspring Global Investments Holdings LLC raised its holdings in shares of Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 143 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at $26,000. Altitude Crest Partners Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter valued at $30,000. Robeco Institutional Asset Management B.V. grew its holdings in shares of Alnylam Pharmaceuticals by 155.7% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 12,513 shares during the last quarter. Finally, V Square Quantitative Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $52,000. Institutional investors own 92.97% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Cantor Fitzgerald reiterated a “neutral” rating and issued a $220.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, September 9th. Barclays lifted their target price on shares of Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Canaccord Genuity Group upped their price target on shares of Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $198.00 to $370.00 in a research report on Friday, August 16th. Finally, Bank of America increased their target price on Alnylam Pharmaceuticals from $295.00 to $307.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Seven research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $279.14.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 15,000 shares of the business’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the transaction, the chief executive officer now directly owns 73,441 shares in the company, valued at $20,563,480. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Dennis A. Ausiello sold 20,250 shares of the firm’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the transaction, the director now directly owns 136 shares of the company’s stock, valued at $35,632. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the sale, the chief executive officer now owns 73,441 shares in the company, valued at approximately $20,563,480. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 57,491 shares of company stock worth $15,446,733. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $271.83 on Tuesday. The business’s 50-day simple moving average is $260.43 and its 200-day simple moving average is $200.28. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $287.55. The firm has a market cap of $34.38 billion, a price-to-earnings ratio of -101.43 and a beta of 0.38.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.61. The company had revenue of $659.83 million for the quarter, compared to analyst estimates of $447.22 million. During the same quarter last year, the business earned ($2.21) EPS. The company’s revenue for the quarter was up 107.0% on a year-over-year basis. As a group, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.